Advice

following a full submission:

abemaciclib (VerzeniosĀ®) is accepted for use within NHSScotland.

Indication under review: for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor* as initial endocrine-based therapy, or in women who have received prior endocrine therapy.

In a phase III randomised study in women with HR-positive, HER2-negative advanced breast cancer, abemaciclib in combination with an aromatase inhibitor significantly increased progression-free survival compared with aromatase inhibitor monotherapy.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of abemaciclib. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

*For SMC advice relating to the use of abemaciclib in combination with fulvestrant in this setting, please refer to SMC2179.

Medicine details

Medicine name:
abemaciclib (Verzenios)
SMC ID:
SMC2135
Indication:
Women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published:
13 May 2019